Hyaluronic Acid Hydrogel Incorporating Dexpanthenol-Engineered Extracellular Vesicles for Accelerated Wound Closure and Mitigated Secondary Infection Risk
Pharmaceutics · 13.08.2026 · 18 (8) · 1003
DOI: 10.3390/pharmaceutics18081003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.08.2026. Verfasst von Hyeyoung Shin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, CHA University, Seongnam 13488, Gyeonggi, Republic of Korea. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Medical Device Development Fund.
Abstract (Originalsprache)
Background
Loss of epithelial integrity leaves the wound bed open to opportunistic bacterial colonization, and the risk of secondary infection persists for as long as the defect remains unclosed. Wound dressings must therefore provide an immediate external barrier while accelerating restoration of the skin’s own barrier. This study aims to develop and evaluate a bioactive nanotechnological platform comprising dexpanthenol (Dxp)-engineered extracellular vesicles (EVs) embedded within cross-linked hyaluronic acid hydrogels (HA@Dxp-engineered EVs) for targeted wound treatment and protection against external contaminants.
Methods
EVs were engineered via exogenous (extrusion; Exo EV) and endogenous (co-incubation; Endo EV) strategies to encapsulate Dxp. The physicochemical properties of the HA@Dxp-engineered EV systems were characterized, and their therapeutic efficacy was validated through in vitro assays, including fibroblast migration and endothelial tube formation, and in vivo using a full-thickness excisional wound model in mice.
Results
Both engineering strategies successfully encapsulated Dxp while preserving the structural integrity of the EVs. The HA hydrogel enabled sustained EV release and provided a physical barrier. In vitro, HA@Endo EVs significantly promoted fibroblast proliferation, migration, and the formation of mature capillary-like networks in HUVECs compared to controls. In vivo, the HA@Endo EV group demonstrated accelerated wound closure, achieving 99.88% healing by day 10, and promoted tissue remodeling with upregulated expression of COL1A1, VEGF, and HIF-1α.
Conclusions
The HA@Endo EV system provides a dual-action strategy against secondary infection risk. It supplies an immediate physical barrier over the wound bed and simultaneously accelerates re-epithelialization, thereby shortening the interval during which the tissue remains exposed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Science, CHA University, Seongnam 13488, Gyeonggi, Republic of Korea.
- College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- ORANDBIO Co., Ltd., Uiwang 16108, Gyeonggi, Republic of Korea.
- Department of Orthopedic Surgery, CHA University, CHA Bundang Medical Center, Seongnam 13496, Gyeonggi, Republic of Korea.
ORCID-Profile: Juwon Youn, Chang Kyu Lee, Dong Keun Han
Förderung
- Korea Medical Device Development Fund
Zitieren
APA
Shin, H., Youn, J., Lee, C. K., Baik, S., Ahn, T. K., & Han, D. K. (2026). Hyaluronic Acid Hydrogel Incorporating Dexpanthenol-Engineered Extracellular Vesicles for Accelerated Wound Closure and Mitigated Secondary Infection Risk. Pharmaceutics, 18(8), 1003. https://doi.org/10.3390/pharmaceutics18081003
Vancouver
Shin H, Youn J, Lee CK, Baik S, Ahn TK, Han DK. Hyaluronic Acid Hydrogel Incorporating Dexpanthenol-Engineered Extracellular Vesicles for Accelerated Wound Closure and Mitigated Secondary Infection Risk. Pharmaceutics. 2026;18(8):1003. doi:10.3390/pharmaceutics18081003
BibTeX
@article{Shin2026,
author = {Shin, Hyeyoung and Youn, Juwon and Lee, Chang Kyu and Baik, Seungwoon and Ahn, Tae-Keun and Han, Dong Keun},
title = {Hyaluronic Acid Hydrogel Incorporating Dexpanthenol-Engineered Extracellular Vesicles for Accelerated Wound Closure and Mitigated Secondary Infection Risk},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {1003},
doi = {10.3390/pharmaceutics18081003}
}
EUVIMED